What is Evofem?
Evofem Biosciences, Inc. operates at the intersection of biotechnology and consumer health, specifically targeting the reproductive health market. The company is recognized for its focus on developing and commercializing novel therapeutics that provide women with greater autonomy and choice in their healthcare decisions. By identifying gaps in existing medical paradigms, Evofem has positioned itself as a critical player in the life sciences landscape, moving beyond traditional models to offer targeted, patient-centric interventions. Their operational strategy emphasizes the rapid deployment of health innovations, supported by a robust network of institutional backers and strategic partners who share a vision for transforming women's health outcomes on a global scale.
How much funding has Evofem raised?
Evofem has raised a total of $154.8M across 6 funding rounds:
Private Equity
$25M
Series C
$20.6M
Series D
$25M
Other Financing Round
$80M
Stock Offering
$3.3M
Private Equity
$925K
Private Equity (2009): $25M with participation from Undisclosed
Series C (2012): $20.6M led by RUSNANO, Alta Partners, AMOREPACIFIC US, and RMI Partners
Series D (2016): $25M supported by Woodford Investment Management
Other Financing Round (2019): $80M featuring PDL, Woodford Investment Management, and Invesco Asset Management
Stock Issuance/Offering (2024): $3.3M backed by Aditx
Private Equity (2025): $925K, investors not publicly disclosed
Key Investors in Evofem
Woodford Investment Management
A financial services firm that managed various investment funds, including the Woodford Equity Income Fund and Woodford Patient Capital Trust, with a focus on providing managed investment solutions.
Invesco Asset Management
A global, publicly owned investment manager providing services to institutional and retail clients, managing diverse portfolios across equity, fixed income, and alternative markets.
Alta Partners
A prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
What's next for Evofem?
Looking ahead, the infusion of capital from the most recent strategic investment will likely be directed toward scaling commercial operations and expanding the reach of their core product portfolio. As the company navigates the complexities of the reproductive health market, the focus will remain on operational efficiency and the continued validation of their clinical pipeline. With a history of sustained backing from diverse institutional investors, Evofem is well-positioned to leverage its current liquidity to navigate regulatory hurdles and enhance its competitive moat. The firm's ability to maintain investor confidence through various funding cycles suggests a resilient long-term strategy aimed at achieving sustainable growth and market leadership in the specialized healthcare domain.
See full Evofem company page
